Research and Development of SB308 Regenerative Cell Therapy
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「Regenerative cell therapy SB308 is a muscle stem cell product derived from bone marrow. Although it remains at the research stage, development will proceed with a view to future applications in muscular dystrophy and other diseases.」
The policy of developing SB308 as a research-stage drug candidate, with a view to applications in muscular dystrophy and other conditions, has been reaffirmed. - FY2020RestatedAnnual report
「Regenerative cell therapy SB308 is a muscle stem cell product derived from bone marrow. Although it remains at the research stage, development will proceed with a view to future applications in muscular dystrophy and other diseases.」
The policy of developing SB308 as a research-stage drug candidate, with a view to applications in muscular dystrophy and other conditions, has been reaffirmed. - FY2019RestatedAnnual report
「Regenerative cell therapy SB308 is a muscle stem cell product derived from bone marrow. Although it remains at the research stage, development will proceed with a view to future applications in muscular dystrophy and other diseases.」
The policy of developing SB308 as a research-stage drug candidate, with a view to applications in muscular dystrophy and other conditions, has been reaffirmed. - FY2017First statedAnnual report
「Regenerative cell therapy SB308 is a muscle stem cell product derived from bone marrow. Although it remains at the research stage, development will proceed with a view to future applications in muscular dystrophy and other diseases.」
The company is developing bone marrow-derived muscle stem cell SB308 as a research-stage drug candidate, with a view to applications in muscular dystrophy and other conditions.